What Are United Farms CBD Gummies Side Effects? A Scientific Overview - Mustaf Medical

Introduction

Imagine a busy professional juggling conference calls, a restless night of fragmented sleep, and occasional joint soreness from a weekend hike. Over the past year, many people in similar situations have turned to over‑the‑counter cannabidiol (CBD) products-especially gummies-for a convenient, discreet way to address stress, sleep quality, or mild inflammation. United Farms' CBD gummies are among the most widely marketed options, yet scientific literature on their side‑effect profile remains limited and sometimes contradictory. This article synthesizes current clinical and pre‑clinical findings to help readers understand what is known, what remains uncertain, and why individualized medical advice is essential when considering any cbd gummies product for humans.

Background

United Farms CBD gummies are edible confectionaries that contain cannabidiol extracted from the hemp plant (Cannabis sativa L.) and are marketed as a dietary supplement rather than a pharmaceutical drug. In the United States, products with less than 0.3 % Δ⁹‑tetrahydrocannabinol (THC) fall under the 2018 Farm Bill's definition of "hemp," allowing them to be sold without FDA approval, provided they make no disease‑treatment claims.

Research interest in CBD has expanded dramatically since 2018, with PubMed indexing over 2,400 articles on "cannabidiol" by early 2026. Human trials have examined oral CBD for anxiety, seizure disorders, chronic pain, and sleep disturbances, but most studies use purified isolates or oil formulations. Gummies introduce a matrix of sugars, gelatin, and sometimes additional nutraceuticals, which can influence absorption and tolerability. Consequently, side‑effect data specific to gummies-particularly those produced by United Farms-must be interpreted within the broader context of oral CBD research.

Science and Mechanism

Absorption and Metabolism

When a gummy is ingested, the candy matrix dissolves in the stomach, releasing CBD in a lipophilic form that partitions into the intestinal mucosa. Oral bioavailability of CBD is low, estimated between 6 % and 15 % in healthy adults, primarily due to extensive first‑pass metabolism by hepatic cytochrome P450 enzymes (CYP3A4 and CYP2C19). A 2023 randomized crossover study comparing CBD oil, capsules, and gummies in 30 participants reported mean plasma CBD concentrations of 45 ng/mL (oil), 31 ng/mL (capsules), and 38 ng/mL (gummies) after a 25 mg dose, suggesting modestly higher bioavailability for gummies relative to capsules but still lower than sublingual oil.

The presence of dietary fats can increase absorption; some United Farms gummies incorporate medium‑chain triglyceride (MCT) oil to enhance lipophilicity. However, the sugar‑rich matrix may slow gastric emptying, potentially flattening the time‑to‑peak concentration (Tmax) from 1–2 hours (oil) to 2–3 hours (gummies). These pharmacokinetic nuances matter because side‑effect intensity often correlates with peak plasma levels.

Pharmacodynamics

CBD interacts with the endocannabinoid system (ECS) indirectly. Unlike Δ⁹‑THC, it has low affinity for CB1 and CB2 receptors but modulates them through negative allosteric signaling and inhibition of fatty acid amide hydrolase (FAAH), which degrades the endogenous ligand anandamide. Elevated anandamide can produce anxiolytic and analgesic effects. CBD also influences non‑cannabinoid receptors: it agonizes the serotonin 5‑HT1A receptor, antagonizes GPR55, and activates peroxisome proliferator‑activated receptor gamma (PPAR‑γ).

Evidence for these mechanisms varies in strength. The FDA‑approved Epidiolex (purified CBD) shows clear anticonvulsant activity supported by Phase III trials, whereas data on low‑dose, over‑the‑counter products are largely observational. In vitro studies suggest CBD can reduce pro‑inflammatory cytokine release (IL‑6, TNF‑α), offering a biological rationale for claims about inflammation relief, yet human confirmation at typical gummy dosages (5–25 mg per serving) remains limited.

Dosage Ranges and Response Variability

Clinical trials of oral CBD have used dosages ranging from 10 mg to 1,500 mg per day. Most consumer gummies contain 5 mg, 10 mg, or 25 mg per piece. A 2024 meta‑analysis of 12 placebo‑controlled studies reported that doses ≤25 mg were associated with modest reductions in self‑reported anxiety scores without a statistically significant increase in adverse events compared with placebo. Higher doses (>100 mg) correlated with greater incidence of hepatic enzyme elevations and diarrhea.

Inter‑individual factors-age, body mass index, genetic polymorphisms of CYP enzymes, and concurrent medications-affect both pharmacokinetics and pharmacodynamics. For example, carriers of the CYP2C19*2 loss‑of‑function allele may experience higher systemic CBD exposure, potentially amplifying side effects.

Emerging Evidence

Some 2025 pilot studies explored the impact of CBD gummies on sleep architecture using polysomnography. Results indicated a trend toward increased total sleep time and reduced wake after sleep onset at 20 mg nightly, but the sample sizes (n = 12–18) were insufficient for definitive conclusions. Likewise, ongoing trials at the University of Colorado are investigating CBD gummies as an adjunct to physiotherapy for osteoarthritis pain; preliminary safety data show no serious adverse events, but efficacy outcomes are pending.

Overall, the mechanistic picture suggests that CBD-delivered via gummies-can influence multiple neurochemical pathways, but the magnitude of effect at typical consumer dosages remains modest and highly variable.

Comparative Context

Source/Form	Absorption / Metabolic Impact	Intake Ranges Studied (Typical)	Main Limitations	Populations Studied
CBD Oil (sublingual)	Bypasses stomach, higher bioavailability (~15‑20 %)	10–150 mg/day	Variable lipophilicity of carrier oils; taste tolerance	Adults with anxiety, epilepsy, chronic pain
CBD Gummies (edible)	Low‑to‑moderate bioavailability (6‑15 %); first‑pass effect	5–25 mg per piece, 10‑75 mg/day	Sugar matrix may affect gastric emptying; less precise dosing	General adult consumers; limited clinical data
Full‑Spectrum Hemp Powder	Variable due to fiber content; slower release	200‑600 mg/day (plant material)	High variability in cannabinoid profile; possible THC exposure	Athletes, wellness seekers
Synthetic Cannabinoid (e.g., dronabinol)	High oral bioavailability (~30 %); metabolized to active THC	2.5‑10 mg/day (THC equivalent)	Contains psychoactive THC; regulatory restrictions	Cancer cachexia, nausea
Placebo (carrier only)	No CBD; serves as control	N/A	No pharmacologic activity; potential placebo effect	All trial arms

Population Trade‑offs

Adults seeking mild anxiety relief – Sublingual oil offers higher systemic exposure with fewer sugars, making it preferable for individuals monitoring caloric intake. Gummies provide a discreet, taste‑masked option but may deliver lower peak concentrations.

Older adults with polypharmacy – The first‑pass metabolism of gummies raises the possibility of drug‑drug interactions via CYP enzymes. Oil formulations can be titrated more precisely, which may reduce interaction risk.

Athletes concerned about doping – Full‑spectrum powders may contain trace THC, risking positive tests, whereas isolated CBD gummies (≤0.3 % THC) are generally considered low risk, though testing policies vary.

Safety

Commonly reported side effects (incidence ≤15 % in trials ≤25 mg daily):
- Mild gastrointestinal upset (nausea, diarrhea)
- Dry mouth (xerostomia)
- Drowsiness or slight fatigue, especially when taken before bedtime

Less frequent but clinically notable events (incidence ≤2 %):
- Elevated liver enzymes (ALT, AST) – observed mainly at doses >100 mg/day in epilepsy trials
- Hypotension or dizziness – reported in isolated cases, often when combined with antihypertensive agents

Populations requiring caution
- Pregnant or lactating individuals – Animal studies suggest potential fetal development effects; human data are insufficient.
- Individuals on anticoagulants (e.g., warfarin) – CBD can inhibit CYP2C9, potentially altering INR levels.
- People with hepatic impairment – Reduced metabolic capacity may increase systemic CBD, raising risk of hepatotoxicity.

Potential drug interactions
CBD is a moderate inhibitor of CYP3A4 and CYP2C19. Concomitant use with medications metabolized by these enzymes (e.g., certain antiepileptics, antidepressants, benzodiazepines) may increase plasma concentrations of the co‑administered drug, necessitating dose adjustments under medical supervision.

Why professional guidance matters
Because the side‑effect profile depends on dosage, formulation, individual metabolism, and concomitant therapies, clinicians can help balance potential benefits against risks, particularly for vulnerable groups.

FAQ

1. Can United Farms CBD gummies cause a positive drug test?
Most gummies are formulated to contain less than 0.3 % THC, the threshold for legal hemp products. While the risk of a positive urine test is low, trace THC can accumulate with high‑frequency use, especially in sensitive immunoassays. Athletes subject to strict anti‑doping rules should verify the product's THC content and consider using a THC‑free isolate.

2. Are the side effects of gummies different from CBD oil?
The underlying compound (CBD) is the same, so core side effects-dry mouth, drowsiness, gastrointestinal upset-are shared. However, gummies introduce sugars and gelatin, which may cause additional GI irritation in sensitive individuals. Moreover, the slower absorption of gummies can lead to a milder, more prolonged drowsiness compared with the quicker peak from sublingual oil.

3. How long do side effects last after stopping the gummies?
Because CBD's half‑life after oral ingestion is roughly 2–5 hours, most acute side effects resolve within 24 hours. Persistent liver enzyme elevations, observed only at high doses, typically normalize within weeks after discontinuation, but liver function should be monitored if elevated values occur.

4. Can I take CBD gummies with my prescription anxiety medication?
CBD can interact with serotonergic agents (e.g., SSRIs) by influencing CYP enzymes and 5‑HT1A receptors. While many patients tolerate combined use without severe effects, the interaction potential warrants a discussion with a prescriber to adjust dosing or monitor for increased sedation.

5. Do gummies work for chronic inflammation?
Pre‑clinical studies show CBD can suppress inflammatory cytokines, and limited human data suggest modest pain reduction at doses ≥20 mg daily. However, robust clinical trials specifically evaluating gummies for chronic inflammatory conditions are lacking, making efficacy conclusions premature.

Disclaimer

This content is for informational purposes only. Always consult a healthcare professional before starting any supplement.